Erik van Werkhoven
Overview
Explore the profile of Erik van Werkhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2768
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linschoten M, Geels J, van Werkhoven E, Visser-Wisselaar H, Chamuleau M, Teske A, et al.
Cardiooncology
. 2025 Jan;
11(1):8.
PMID: 39875951
Background: Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the...
2.
van Werkhoven L, Milder M, Hoogeman M, van Werkhoven E, Nout R, Nuyttens J
Int J Radiat Oncol Biol Phys
. 2024 Dec;
PMID: 39694145
Purpose: This study reports on the clinical outcomes of the single-arm phase-2 STEAL trial investigating online adaptive stereotactic body radiation therapy (SBRT) for abdominal-pelvic lymph node (A-P LN) oligometastases. Methods...
3.
den Toom W, Negenman E, Willemssen F, van Werkhoven E, Porte R, de Wilde R, et al.
Clin Transl Radiat Oncol
. 2024 Nov;
49:100878.
PMID: 39512948
Purpose/objectives: To evaluate if stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) has a durable effect on tumor control and can be delivered safely. Materials/methods: Patients included in this retrospective...
4.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Opdam M, van Rossum A, Hoogstraat M, Bounova G, Horlings H, van Werkhoven E, et al.
iScience
. 2024 Aug;
27(8):110425.
PMID: 39206149
The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene...
5.
de Jonge A, Bruins W, Duetz C, Korst C, Rentenaar R, Cosovic M, et al.
Haematologica
. 2024 Jul;
109(11):3760-3765.
PMID: 38961740
No abstract available.
6.
de Jonge A, Duetz C, Bruins W, Korst C, Rentenaar R, Cosovic M, et al.
Blood Adv
. 2024 Jan;
8(5):1094-1104.
PMID: 38191686
Patients with high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-MYC/BCL2) respond poorly to immunochemotherapy compared with patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) without a...
7.
Vliek S, Hilbers F, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):75.
PMID: 37689749
Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients...
8.
de Jonge A, van Werkhoven E, Dinmohamed A, Nijland M, Zwinderman A, Bossuyt P, et al.
Blood Cancer J
. 2023 May;
13(1):85.
PMID: 37217463
Patients with MYC rearranged (MYC-R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Previously, we demonstrated in a single-arm phase II trial (HOVON-130) that addition of lenalidomide to R-CHOP...
9.
de Vries H, Ottenhof S, Rafael T, van Werkhoven E, Pos F, van Rhijn B, et al.
Eur Urol Open Sci
. 2023 Jan;
47:29-35.
PMID: 36601037
Background: Penile cancer (PeCa) is rare, and the survival of patients with advanced disease remains poor. A better understanding of where treatment fails could aid the development of new treatment...
10.
van der Voort A, Liefaard M, van Ramshorst M, van Werkhoven E, Sanders J, Wesseling J, et al.
Breast
. 2022 Aug;
65:110-115.
PMID: 35921798
Background: Pathologic complete response (pCR) rates in early stage HER2-positive breast cancer improved after pertuzumab was added to neoadjuvant treatment. However, survival benefit is less-well established and seems mostly limited...